Flores Joan Ericka, Thompson Alexander J, Ryan Marno, Howell Jessica
Department of Gastroenterology, St. Vincent's Hospital Melbourne, Fitzroy, VIC 3065, Australia.
Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia.
Vaccines (Basel). 2022 May 17;10(5):793. doi: 10.3390/vaccines10050793.
Over 1.5 million preventable new hepatitis B infections continue to occur each year and there are an estimated 296 million people living with chronic hepatitis B infection worldwide, resulting in more than 820,000 deaths annually due to liver cirrhosis and hepatocellular carcinoma (HCC). Hepatitis B vaccination remains the cornerstone of public health policy to prevent HCC and a vital component of the global hepatitis B elimination response. The WHO has set a 90% vaccination target to achieve hepatitis B elimination by 2030; however, there is wide variability in reported birth dose coverage, with global coverage at only 42%. In this review, we outline the global trends in hepatitis B vaccination coverage and the impact of hepatitis B vaccination on HCC incidence and discuss the challenges and enabling factors for achieving WHO 2030 hepatitis B vaccination coverage targets.
每年仍有超过150万例可预防的新发乙型肝炎感染病例出现,全球估计有2.96亿慢性乙型肝炎感染者,每年因肝硬化和肝细胞癌(HCC)导致的死亡人数超过82万。乙肝疫苗接种仍然是预防肝细胞癌的公共卫生政策基石,也是全球消除乙肝应对措施的重要组成部分。世界卫生组织设定了到2030年实现90%乙肝疫苗接种率以消除乙肝的目标;然而,报告的首剂疫苗接种覆盖率差异很大,全球覆盖率仅为42%。在本综述中,我们概述了乙肝疫苗接种覆盖率的全球趋势以及乙肝疫苗接种对肝细胞癌发病率的影响,并讨论了实现世界卫生组织2030年乙肝疫苗接种覆盖率目标所面临的挑战和有利因素。